LinkMed: Anders Karlsson New CEO of AbSorber

* Reuters is not responsible for the content in this press release.

Thu Apr 17, 2008 3:13am EDT 

STOCKHOLM, Sweden--(Business Wire)--
Regulatory News:

   Anders Karlsson has been appointed the new CEO of LinkMed's
portfolio company AbSorber. Karlsson has been COO of the company since
the fall 2007. AbSorber's former CEO Ingemar Lagerlof, who is also CEO
of LinkMed, is taking on the role of member of the board of AbSorber.

   "Anders Karlsson has done an excellent job since he joined
AbSorber in the fall. He demonstrated early on that he has the drive
that is necessary for the company to achieve success in the complex
transplantation market," says LinkMed's CEO, Ingemar Lagerlof.

   "My goal is to establish AbSorber as an innovative, world leading
supplier in the transplantation sector. Our portfolio provides us with
excellent potential to achieve this goal," says Anders Karlsson.

   Karlsson has extensive experience from the pharmaceutical
industry. He has previously worked in the transplantation sector and
was the CEO of Novartis in Norway.

   AbSorber develops products that facilitate more successful
transplantations. Today, AbSorber has one commercial product, a
standardized transplantation test XM-ONE(R), used to evaluate organ
transplantation risk. AbSorber has entered into a global sales
agreement for XM-ONE(R) with the U.S. medtech company BD. AbSorber is
also developing an ABO column to facilitate organ transplantations
between people of different blood groups and a diagnostic test that
measures the occurrence of blood group antigens. The company was
established in 1999 to commercialize findings from research carried
out by professors Jan Holgersson and Suchitra Holgersson at the
Karolinska University Hospital, in Huddinge, outside Stockholm.

   LinkMed owns 42.1 percent of AbSorber.

   LinkMed develops life-science companies in collaboration with
innovators. By contributing entrepreneurship and capital, LinkMed has
created a portfolio of twelve companies, six in drug development and
biotechnology and six in medical technology. The LinkMed share is
listed on the OMX Nordic Exchange Stockholm and the company's largest
partners are FastPartner, Koncentra Holding and the founder Ingemar
Lagerlof. See www.linkmed.se for more information.

   This information was brought to you by Cision
http://newsroom.cision.com

LinkMed
Ingemar Lagerlof, CEO, +46 8 508 939 93

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.